| Dr Linda Doan, MD | |
|
850 Health Sciences Rd, Irvine, CA 92617-3058 | |
| (949) 824-0606 | |
| Not Available |
| Full Name | Dr Linda Doan |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 11 Years |
| Location | 850 Health Sciences Rd, Irvine, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225477268 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ND0900X | Dermatology - Dermatopathology | 156270 (California) | Secondary |
| 207N00000X | Dermatology | 156270 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of California Irvine Medical Center | Orange, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Uci Department Of Dermatology | 7113920992 | 25 |
News Archive
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
Standardizing last names and address information can improve the linking of patient health records by as much as 8 percent - more than 2 billion records - and enhance data available to clinicians to inform their care decisions.
According to latest breakthrough in research, a blood test to detect eight common cancers, even before their symptoms begin to appear, may become a reality soon. The study report appears in the latest issue of the journal Science and gives hope for early detection of these deadly diseases when it could still be treated more effectively.
Drugs for HIV/AIDS and other disease should be affordable and accessible to all people who need them, advocates from 15 countries who met recently in New Delhi to examine issues surrounding intellectual property rights said, the Hindustan Times reports.
Researchers in Canada have conducted a study suggesting that novel Cannabis sativa extracts may decrease levels of the host cell receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain viral entry to target tissues.
› Verified 8 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558311811 PECOS PAC ID: 1951201185 Enrollment ID: O20040112000598 |
News Archive
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
Standardizing last names and address information can improve the linking of patient health records by as much as 8 percent - more than 2 billion records - and enhance data available to clinicians to inform their care decisions.
According to latest breakthrough in research, a blood test to detect eight common cancers, even before their symptoms begin to appear, may become a reality soon. The study report appears in the latest issue of the journal Science and gives hope for early detection of these deadly diseases when it could still be treated more effectively.
Drugs for HIV/AIDS and other disease should be affordable and accessible to all people who need them, advocates from 15 countries who met recently in New Delhi to examine issues surrounding intellectual property rights said, the Hindustan Times reports.
Researchers in Canada have conducted a study suggesting that novel Cannabis sativa extracts may decrease levels of the host cell receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain viral entry to target tissues.
› Verified 8 days ago
| Entity Name | Uci Department Of Dermatology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518916527 PECOS PAC ID: 7113920992 Enrollment ID: O20060816000496 |
News Archive
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
Standardizing last names and address information can improve the linking of patient health records by as much as 8 percent - more than 2 billion records - and enhance data available to clinicians to inform their care decisions.
According to latest breakthrough in research, a blood test to detect eight common cancers, even before their symptoms begin to appear, may become a reality soon. The study report appears in the latest issue of the journal Science and gives hope for early detection of these deadly diseases when it could still be treated more effectively.
Drugs for HIV/AIDS and other disease should be affordable and accessible to all people who need them, advocates from 15 countries who met recently in New Delhi to examine issues surrounding intellectual property rights said, the Hindustan Times reports.
Researchers in Canada have conducted a study suggesting that novel Cannabis sativa extracts may decrease levels of the host cell receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain viral entry to target tissues.
› Verified 8 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174662555 PECOS PAC ID: 8325131378 Enrollment ID: O20100513000487 |
News Archive
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
Standardizing last names and address information can improve the linking of patient health records by as much as 8 percent - more than 2 billion records - and enhance data available to clinicians to inform their care decisions.
According to latest breakthrough in research, a blood test to detect eight common cancers, even before their symptoms begin to appear, may become a reality soon. The study report appears in the latest issue of the journal Science and gives hope for early detection of these deadly diseases when it could still be treated more effectively.
Drugs for HIV/AIDS and other disease should be affordable and accessible to all people who need them, advocates from 15 countries who met recently in New Delhi to examine issues surrounding intellectual property rights said, the Hindustan Times reports.
Researchers in Canada have conducted a study suggesting that novel Cannabis sativa extracts may decrease levels of the host cell receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain viral entry to target tissues.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Linda Doan, MD 200 S Manchester Ave Ste 300, Orange, CA 92868-3219 Ph: (714) 456-2986 | Dr Linda Doan, MD 850 Health Sciences Rd, Irvine, CA 92617-3058 Ph: (949) 824-0606 |
News Archive
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
Standardizing last names and address information can improve the linking of patient health records by as much as 8 percent - more than 2 billion records - and enhance data available to clinicians to inform their care decisions.
According to latest breakthrough in research, a blood test to detect eight common cancers, even before their symptoms begin to appear, may become a reality soon. The study report appears in the latest issue of the journal Science and gives hope for early detection of these deadly diseases when it could still be treated more effectively.
Drugs for HIV/AIDS and other disease should be affordable and accessible to all people who need them, advocates from 15 countries who met recently in New Delhi to examine issues surrounding intellectual property rights said, the Hindustan Times reports.
Researchers in Canada have conducted a study suggesting that novel Cannabis sativa extracts may decrease levels of the host cell receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain viral entry to target tissues.
› Verified 8 days ago
Dr. Marit Kay Kreidel, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 6 Willard, Dept Of Dermatology, Irvine, CA 92604 Phone: 949-262-5780 | |
Christopher Bransby Zachary, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Plz, Irvine, CA 92697 Phone: 949-824-5515 Fax: 949-824-7454 | |
Justin David Arnold, MD Dermatology Medicare: Medicare Enrolled Practice Location: Department Of Dermatology Administrative Office, 118 Medical Surge I, Irvine, CA 92697 Phone: 949-824-5515 | |
Gary Cheukman Lee, M.D. , PH.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4980 Barranca Pkwy Ste 202, Irvine, CA 92604 Phone: 949-733-1336 Fax: 949-733-3387 | |
Dr. Marjon Vatanchi, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 6865 Alton Pkwy Ste 210, Irvine, CA 92618 Phone: 949-800-8551 Fax: 949-800-8090 | |
Dr. Sogol Saghari, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 113 Waterworks Way Ste 235, Irvine, CA 92618 Phone: 949-679-6564 Fax: 949-679-6554 | |
Jessica Shiu, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 118 Medical Surge 1, Irvine, CA 92697 Phone: 949-824-4405 |